Apolipoprotein A-I (apoA-I) is the major protein component of high density lipoprotein (HDL) comprising approximately 70% of the apolipoprotein content of the particle ( 1 ) . ApoA-I is synthesized in the liver and intestine as the 267 amino acid precursor, preproapoA-I ( 2 ). Cleavage of a signal peptide from the preproapoA-I N-terminus leads to the formation of proapoA-I, which is secreted into circulation. A further cleavage by bone morphogenic protein-1
Excision and recovery of apoA-I. Once the apoA-I band was visible adjacent to the 25 kDa band (pre-stained in pink), the stained gel piece was aligned with the larger, unstained gel piece ( Fig. 1A ) . A section across the larger gel piece was then excised from where the apoA-I band was inferred to run by comparison with the stained piece. Subsequent staining of the gel after excision revealed the accuracy of excision ( Fig. 1B ) . The excised gel slice was cut into 2 to 3 mm sized fragments mm fragments and placed into 5 ml of deionized water overnight with gentle agitation. The following day, the eluted apoA-I protein was concentrated 10-fold using a Vivaspin column and left overnight at 4°C to maximize the amount of protein recovered from the concentrating column. The recovered protein was delipidated in 9 vols of 3:1 ethanol:diethyl ether for 6 h at Ϫ 80°C, pelleted by centrifugation at 13,000 rpm for 15 min and washed in diethyl ether. The protein precipitate was pelleted again by centrifugation at 13,000 rpm for 5 min, the solvent evaporated under nitrogen gas, and the protein pellet resuspended in PBS.
Chromatography purifi cation of apoA-I. ApoA-I was alternatively isolated by size-exclusion chromatography. HDL was isolated from 250 ml of donor plasma using the method of Havel ( 17 ) in a Beckman Optima L-70 ultracentrifuge with a Ti60 rotor. HDL was lyophilized, resuspended, and delipidated with a 1:1:2 methanol:chloroform:ether mix followed by a 1:3 methanol:ether mix then washed with ether. The protein pellet was resuspended in urea buffer (6 M urea, 50 mM Tris, pH 8.0). The HDL proteins (50 mg) were fractionated by size-exclusion chromatography on a Sephacryl S-300 column (100 × 3 cm) at a fl ow rate of 20 ml/h in urea buffer. One hundred 5 ml fractions were collected and protein-containing fractions were analyzed for apoA-I content and purity by SDS-PAGE. Fractions containing pure apoA-I were pooled and dialyzed against PBS for several days.
Analysis of purity and yield. The protein concentration of purifi ed samples was measured by the Bradford assay ( 18 ) . Samples were separated on 10% SDS-PAGE gels and either stained with silver stain ( 19 ) , or transferred to nitrocellulose membrane for Western blot analysis with a polyclonal antibody to apoA-I. Antibody binding was detected with an HRP-conjugated antibody and bands were visualized using the ECL detection system on a Fuji Film LAS-3000 Imager (Tokyo, Japan). Protein samples were also run on 1% agarose gels using the Helena TITAN electrophoresis system (Helena Laboratories, Beaumont, TX) and stained with Amido Black.
The molecular weight of both the gel-purifi ed and chromatography-purifi ed apoA-I was determined by MALDI-time-of-fl ight (TOF) MS on an Applied Biosystems 4800 MALDI-TOF/TOF analyzer (Framingham, MA). For protein identifi cation, mass spectra were acquired on a tryptic digest of the purifi ed apoA-I samples by MALDI-TOF/TOF MS.
Preparation of rHDL complexes. The interaction of the purifi ed apoA-I protein with lipid was examined by preparation of rHDL using the cholate-lipid dispersion method ( 20 ) . DMPC was used as the phospholipid in this case and complexes prepared with a 100:1:100 molar ratio of DMPC:apoA-I:sodium cholate. The rHDL complexes were analyzed on 1% agarose gels stained with Amido Black.
CD spectroscopy. Purifi ed apoA-I samples were dialyzed into a Tris buffer (10 mM Tris, 10 mM NaCl, pH 7.2) and diluted to 0.1 mg/ml. Circular dichroism (CD) spectra were recorded at 20°C on an Olis DSM 10 spectrophotometer (Olis, Bogart, GA) using a 1 mm path length quartz cuvette. Spectra were recorded between the wavelengths of 260 nm and 195 nm with a 1.0 nm step We have developed an alternative isolation method that is rapid, has a high percentage yield of protein recovery, and can be used with relatively small amounts of plasma. Additionally, this method can be performed using reagents and equipment present in virtually any biochemistry laboratory.
MATERIALS AND METHODS

Materials
Plasma for HDL isolation was obtained from blood donated by a normolipidemic healthy subject after written informed consent. Fibroblasts were cultured from 2 mm skin punch biopsies obtained from members of a Tangier disease family ( 16 ) after written informed consent in a study approved by the regional ethics committee. Precision Plus Dual prestained protein marker was obtained from Bio-Rad Laboratories (Hercules, CA). Vivaspin concentrating columns were from Sartorius Stedim Biotech (Aubagne, France). Sephacryl S-300 was from Pharmacia-Biotech (Piscataway, NJ). Nitrocellulose membrane was purchased from Whatman ( Maidstone, UK). The polyclonal antibody to apoA-I was purchased from Abcam (Cambridge, MA) and the HRP-conjugated detection antibody from Santa Cruz (Santa Cruz, CA). The ECL detection system was from Amersham (Piscataway, NJ). Dimyristoylphosphatidylcholine (DMPC) was from Avanti Polar Lipids (Alabaster, AL). Advanced-DMEM, DMEM, L-glutamine, penicillin/ streptomycin, and amphotericin B were obtained from Invitrogen (Carlsbad, CA). Fetal bovine serum was from Bio International (Auckland, New Zealand). [1, [2] [3] H(N)] cholesterol was from Perkin Elmer (Boston, MA). RAW264.7 murine macrophage cells were from American Type Tissue Collection (Manassas, VA). TO901317 and sodium cholate was from Sigma (St. Louis, MO). All other reagents were analytical grade.
Methods
Isolation of HDL. HDL (1.063 < d < 1.21 g/ml) was isolated from 4 ml of donor plasma by sequential ultracentrifugation of KBr-density adjusted plasma using a Beckman TLA-100 tabletop ultracentrifuge and TLA-100.3 rotor (Beckman Coulter Inc., Brea, CA) and the method of Havel ( 17 ) . Alternatively, HDL was isolated from a smaller volume (1-2 ml) using a TLA-100.2 rotor. Isolated HDL was dialyzed against PBS at 4°C for 48 h. Total HDL protein was quantifi ed by the Bradford assay ( 18 ) .
Separation of apoA-I by electrophoresis.
The proteins in HDL were separated by SDS-PAGE on 1.5 mm 10% -polyacrylamide mini-gels under reducing conditions using a 10-well comb and the Protean III Mini system from Bio-Rad Laboratories. The general layout of the method is given in Fig. 1A . Typically, four gels were run simultaneously. Prestained protein marker was loaded in lanes 1 and 9 and 30 g of HDL protein loaded in each of lanes 2-8 and in lane 10 (i.e., 240 g total HDL protein per gel). Electrophoresis was at 80 V for 30 min, then 40 mA per gel for 80 min. After electrophoresis, the gels were disassembled and sliced vertically midway through lane 9 containing the protein marker. The larger section of the gel, comprising lanes 1-8 and half of lane 9, was placed in deionized water. The smaller section of the gel was rinsed twice in deionized water then rapidly stained in Coomassie stain (0.1% Coomassie Brilliant Blue, 40% ethanol, 10% acetic acid) by microwaving for 1 min and shaking gently for 2-3 min. Destain solution (40% ethanol, 10% acetic acid) was added and the gel piece microwaved for 1 min then shaken for 2-3 min.
at UQ Library, on July 18, 2016 www.jlr.org Downloaded from 9) . Following electrophoresis, the gel was sliced vertically midway through lane 9 and the small gel strip stained with Coomassie Blue to detect HDL proteins. The stained strip was then aligned with the unstained gel and the stained apoA-I band used as a guide for excision of the unstained apoA-I band in lanes 2-8. The band was chopped into small 2-3 mm pieces, covered in deionized water, and the apoA-I protein eluted overnight by gentle agitation. The eluted protein was then concentrated, delipidated, and resuspended in PBS. B: Coomassie Blue-stained gels showing electrophoresis of HDL proteins for apoA-I purifi cation as depicted in A. The gel on the left was stained after excision of the apoA-I band. The gel on the right is an unprocessed gel for comparison.
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Yields for the gel-purifi cation method are given in Table 1 and compared with typical yields for chromatographypurifi ed apoA-I. A typical 'run' of the gel-purifi cation method consists of 16 mini-gels and yields just over 1.3 mg of pure apoA-I protein from 3.4 mg total HDL protein.
Although the total amount of apoA-I protein obtained was much less than the chromatography method, due to the much smaller scale of purifi cation, the percentage yield of protein was higher relative to starting material. Cholesterol effl ux assays. Primary fi broblasts were maintained in Advanced-DMEM and RAW264.7 macrophages in DMEM supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 0.25 g/ ml amphotericin B, 100 units/ml of penicillin, and 100 g/ml of streptomycin. Cells were seeded in 12-well plates and labeled with 0.5 Ci per well of [1, [2] [3] H(N)] cholesterol in serum-containing media for 48 h until confl uent. Cells were washed three times in PBS and incubated for 18 h in serum-free medium. In some cases, the LXR agonist TO901317 (2 M) was added to the serum-free medium to increase ABCA1 expression. Cells were washed again four times in PBS and incubated with serum-free medium containing 10 g/ml apoA-I for 8 h. The medium was collected and centrifuged for 2 min at 5,000 rpm to remove cellular debris and H counts in both the medium and cell fraction for each treatment. The Students's t -test was used to determine any statistical differences between the various apoA-I preparations.
RESULTS
Analysis of purity and yield of gel-purifi ed apoA-I
The gel-purifi ed apoA-I protein was analyzed by both SDS-PAGE and Western blot analysis. Silver staining of the gel-purifi ed protein revealed a single band ( Fig. 2A , lane  2) , which was confi rmed by Western blotting to be apoA-I ( Fig. 2B , lane 2) . Chromatography purifi ed apoA-I was included on the gels as a comparison ( Figs. 2A and B , lane 3) and also showed a single band of apoA-I. The electrophoretic mobility of the purifi ed apoA-I protein was examined by electrophoresis on an agarose gel ( Fig. 2C ) alongside HDL and chromatography purifi ed apoA-I. The gel-purifi ed apoA-I protein, like the chromatography purifi ed apoA-I, showed the expected pre ␤ migratory position ( Fig. 2C , lanes 3 and 4) . Also included on this gel was the gel-purifi ed apoA-I before delipidation ( Fig. 2C , lane 2) . Note the highly negatively charged migration of the apoA-I in this case, likely due to the presence of residual SDS, which is removed on delipidation.
Gel-purifi ed and chromatography-purifi ed apoA-I was tested for the ability to interact with DMPC to form rHDL complexes. Analysis of the complexes by agarose gel electrophoresis ( Fig. 3 ) showed that both preparations bound DMPC to form more negatively charged rHDL complexes that migrated in the ␣ position similar to native HDL.
The molecular weights of the gel-purifi ed and chromatography-purifi ed apoA-I as determined by mass spectrometry were 28,049 Da and 28,058 Da, respectively, which matches well with the theoretical value of 28,078 Da for mature human plasma apoA-I. The Mascot search engine identifi ed >16 signifi cant apoA-I peptide hits (Mascot score >58) from the mass spectra of both the gel-purifi ed and chromatography-purifi ed apoA-I preparations (data blasts from the unaffected individual (wild-type) gave values of around 8-10% cholesterol effl ux ( Fig. 5A ) , with no signifi cant difference in effl ux between the chromatography or the two gel-purifi ed apoA-I preparations, or between the two gel-purifi ed apoA-I preparations. When the two fi broblast cell lines were preincubated with the LXR agonist TO901317 to upregulate ABCA1, cholesterol effl ux increased by approximately 3-fold in the cells from the unaffected individual ( Fig. 5B ) . Again, there was no significant difference in the ability of all three apoA-I preparations to promote cholesterol effl ux under these conditions.
Cholesterol effl ux assays were also conducted in RAW264.7 cells to confi rm the results obtained in primary fi broblasts. Cholesterol effl ux from unstimulated RAW264.7 macrophages was low ( Fig. 5C ) but increased to approximately 6% after preincubation with TO901317. As with the fi broblast cell lines, there was no signifi cant difference Structural analysis of gel-purifi ed apoA-I Gel-purifi ed apoA-I was analyzed using CD to confi rm that the structural integrity of the isolated protein was retained. The CD spectra of gel-purifi ed apoA-I ( Fig. 4 ) were similar to that of chromatography-purifi ed A-I, displaying the two minima at 208 and 222 nm characteristic of proteins with signifi cant ␣ -helical content. The ␣ -helical content was calculated as 46.7% ± 1.7 for chromatographypurifi ed protein and 47.2% ± 2.0 for gel-purifi ed protein. These values agree with experimentally determined values for the ␣ -helical content of lipid-free apoA-I ( 22 ) .
Functional analysis of gel-purifi ed apoA-I
To confi rm that the function of the purifi ed apoA-I protein was retained, we tested the cholesterol effl ux capability of the gel-purifi ed apoA-I alongside the chromatography-purifi ed apoA-I. Cholesterol effl ux assays were conducted in human primary fi broblasts collected from an unaffected and an affected member of a Tangier disease pedigree ( 16 ) and in RAW264.7 macrophage cells. Cholesterol effl ux was also measured to two independent gelpurifi ed apoA-I preparations isolated one month apart.
Cholesterol effl ux assays in Tangier disease fi broblasts showed no signifi cant cholesterol effl ux above the blank (i.e., the effl ux when no acceptor was added to the medium) as expected ( Fig. 5A ). Cholesterol effl ux from fi bro- a Gel purifi cation yields are given from a run of 16 mini-gels. Fig. 4 . Circular dichroism spectra of gel-purifi ed apoA-I. Circular dichroism spectroscopy was conducted on both gel-purifed and chromatography-purifi ed apoA-I. Samples were analyzed in 50 mM Tris, 50 mM NaCl, pH 7.2, at a protein concentration of 100 g/ml at 20°C on an Olis DSM 10 spectrophotometer. Spectra were recorded between the wavelengths of 260 nm and 195 nm with a 1.0 nm step size. The data represent the mean residual ellipticity from three independent measurements after baseline correction.
Fig. 5.
Cholesterol effl ux ability of gel-purifi ed apoA-I. A: Cholesterol effl ux to gel-purifi ed apoA-I from fi broblasts. Two independent preparations of gel-purifi ed apoA-I and a chromatography-purifi ed apoA-I preparation were tested as acceptors in cholesterol effl ux assays performed in primary fi broblasts from a Tangier disease patient and an unaffected subject (wildtype). B: Cholesterol effl ux to gel-purifi ed apoA-I from stimulated fi broblasts. The same apoA-I preparations were tested as acceptors in cholesterol effl ux assays in wild-type fi broblasts with or without incubation in 2 M of the LXR agonist, TO901317. C: Cholesterol effl ux to gel-purifi ed apoA-I from RAW264.7 macrophage cells. ApoA-I preparations were also tested as acceptors in cholesterol effl ux assays performed in RAW264.7 macrophages with or without incubation with 2 M of the LXR agonist, TO901317. In all experiments, cells were loaded with 3 H-cholesterol and incubated with 10 g/ml apoA-I for 8 h. Experiments are presented as mean ± SD of quadruplicate measurements.
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In conclusion, this gel-based method of apoA-I purifi cation reproducibly produces a pure protein preparation that is structurally and functionally equivalent to chromatography-purifi ed apoA-I. It provides a quicker and cheaper alternative to chromatography-based methods for studies requiring multiple isolations of apoA-I from small amounts of plasma.
DISCUSSION
ApoA-I is a multifunctional protein integral for the metabolism of HDL and its many anti-atherogenic properties ( 23 ) . The production of purifi ed apoA-I for research and therapeutic purposes relies largely on recombinant expression and affi nity purifi cation techniques of which there are many different systems available ( 5-10 ). Studies of endogenous apoA-I, however, require the isolation of apoA-I from individual plasma samples. This can be problematic due to lengthy costly procedures that use large amounts of plasma and give low yields ( 13 ) . Established purifi cation protocols use size-exclusion ( 12 ) or ion-exchange chromatography ( 24 ) of apoA-I from isolated HDL. These chromatography-based methods allow for large scale purifi cation but they are not suitable for isolation of apoA-I from multiple individuals and/or small samples such as those available from routine blood tests or from experiments with small animals. In this report, we describe a gel-based method for the rapid isolation of apoA-I from small amounts of human plasma, which yields pure apoA-I with an electrophoretic mobility, phospholipid binding capability, CD spectra, and cholesterol effl ux ability analogous to that of chromatography-purifi ed apoA-I.
The major advantage the gel-purifi cation method has over chromatography is that small volumes of plasma can be used with apoA-I being isolated from just 1-2 ml of plasma. This is a signifi cant advantage in a common situation when only a limited amount of blood from an individual patient is available. It also avoids the need for a larger repeat blood sample thus reducing associated patient compliance and health and safety issues. This method would facilitate the screening of apoA-I from individual patients to look at structural or functional modifi cations to apoA-I as may be present in diseased states such as advanced atherosclerosis or diabetes ( 25, 26 ) . Furthermore, it can potentially be adapted for isolation of apoA-I from animal blood for structural and functional studies. The gel-purifi cation method has some other additional benefi ts over chromatography isolation such as a quicker isolation time, cheaper equipment requirements, and a higher percentage yield of protein. Both methods yield apoA-I with properties similar to that previously reported for native apoA-I.
With regards to yields, the recovery of apoA-I protein from the gel-purifi cation method is higher than the recovery from chromatography, leading to a much improved percentage yield. The caveat here is that the total amount of apoA-I purifi ed by the gel method is much less than with chromatography purifi cation, making it unsuitable when large amounts of apoA-I are required for large scale experiments. In this case, the extra time and costs required to carry out the chromatography are offset by the much larger absolute amount of apoA-I purifi ed. The gel method presented here was performed using a mini-gel system;
